
📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.

ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer

📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.


💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with: ✅ Longer time of clinical benefit (PCWG3) ✅ Longer overall survival ✅ Fewer (S)AE

📣 Published in @EUplatinum : our Letter to the Editor on the @myESMO Clinical Practice Guideline for advanced and metastatic prostate cancer. ⚕️The guideline notes the lack of mCRPC trials comparing ARPI with docetaxel-based chemotherapy 🌐doi.org/10.1016/j.eururo.202…

🙏 A sincere thank you to all participating patients, sites, investigators, clinical teams, collaborators, companies and funders supporting this effort. #ProstateCancer #ClinicalTrials #PrecisionOncology #LiquidBiopsy #ctDNA #mHSPC #Oncology #Urology #PersonalizedMedicine

🎯By integrating liquid biopsy profiling, multi-arm platform methodology, patient-reported outcomes, and international collaboration, ProBio-mHSPC seeks to move from “one-size-fits-all” towards more precise, evidence-based care.

🚨 What makes this trial novel? 🩸🧬ctDNA guidance ⬇️ De-escalation for patients with undetectable ctDNA, testing deferred ADT ⬆️ Biomarker-guided intensification for patients with detectable ctDNA to identify who benefits from docetaxel- or PARP-combinations

🌐 LINK trial protocol manuscript: doi.org/10.1016/j.euf.2026.0…

This research was made possible by the support of: @ALFmedicin , @Cancerfonden , Radiumhemmet Research Funds, @Prostatacancerforbundet, @Vetenskapsradet , Krebsliga beider Basel, & @KomOpTegenKanker THANK YOU! 🙏 [8/8] #CancerResearchMatters

What’s next? 🏥 @ProBioTrial will explore treatment de-escalation for low-ctDNA patients 🔬 Future trials should integrate ctDNA fraction 🩸🧬 as a stratification tool 👨⚕️ ctDNA may guide guide #PrecisionMedicine in all #ProstateCancer patients? [7/8]

Why does this matter? 🧬 Patients with undetectable ctDNA may need less intensive treatment & monitoring. Towards a ctDNA-driven de-escalation strategy? ⚠️ Patients with high ctDNA in their🩸 may benefit from earlier aggressive treatment [6/8]

🏅Secondary result: We found a linear relationship between ctDNA 🩸 levels and outcome: 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome! #PrecisionMedicine [5/8]

🏅Key result: 🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had ➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB) ➡️a 51% longer overall survival (OS) 📉 #CancerBiomarkers [4/8]

We analyzed 220 men with metastatic castration-resistant #ProstateCancer from the @ProBioTrial ➡️139 had detectable ctDNA ➡️81 had undetectable ctDNA What did we find? Patients with undetectable ctDNA lived much longer! 🔬📊 #PrecisionOncology [3/8]

🧬 ctDNA is tumor-derived DNA found in the bloodstream 🩸 📢Our study shows that men with undetectable ctDNA in their #LiquidBiopsy have significantly better survival outcomes 🔍 Full manuscript available on @EurUrolOncol: lnkd.in/em57NHCG [2/8]

🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]